Top Stock: Hemispherx Biopharma Inc. (NYSE Amex: HEB)

Hemispherx Biopharma Inc. is a biopharmaceutical company dedicated to treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body.
Symbol: HEB Exchange: NYSE Amex
  Industry: Biotechnology Web Site: www.hemispherx.net


Published
(MM-DD-YY)
Type Comments
04-28-2009 Update Interview Today's interview focuses on the recent spread of swine influenza.
02-22-2009 Update Interview This is a follow-up interview in light of last week's events.
01-29-2009 Initial Interview Our main concern if the Company was going to run out of money before the FDA decision has been answered, and we're pleased with the response.
01-03-2009 Initial Report In short, Ampligen works and is safe. There are millions of people suffering from CFS all over the world. And so far no other treatment is available. If Ampligen is approved by the FDA, it has a high chance of becoming a blockbuster drug.
06-03-2006 2006 Report (pdf) This is our first report we wrote on Hemispherx back in 2006. Although the stock price has come down significantly since then, we believe it's still a good investment.